|1.||Schwedhelm, Edzard: 4 articles (10/2007 - 09/2006)|
|2.||Benndorf, Ralf A: 4 articles (10/2007 - 09/2006)|
|3.||Maas, Renke: 4 articles (10/2007 - 09/2006)|
|4.||Appel, Daniel: 4 articles (10/2007 - 09/2006)|
|5.||Böger, Rainer H: 3 articles (10/2007 - 09/2006)|
|6.||Jiang, Ru: 2 articles (01/2010 - 01/2009)|
|7.||Chen, Hui: 2 articles (01/2010 - 01/2009)|
|8.||Silberhorn, Elisabeth: 2 articles (04/2007 - 09/2006)|
|9.||White, William B: 2 articles (04/2007 - 09/2003)|
|10.||Schulze, Friedrich: 2 articles (03/2007 - 09/2006)|
08/01/1985 - "The rate-pressure product was significantly greater with nisoldipine than with placebo at the onset of ischemia and at peak exercise (22.8 +/- 1.1 versus 20 +/- 1.4 X 10(3) U for the 20 mg dose; p less than 0.01). "
03/15/1991 - "The results indicate that nisoldipine was effective in improving all exercise parameters and only partially effective in suppressing ischemia during daily activity."
01/01/1989 - "[Protective effects of m-nisoldipine and nisoldipine on myocardial damage in working rabbit hearts after ischemia-reperfusion]."
07/01/1992 - "The improved functional recovery of reperfused myocardium in dogs pretreated with nisoldipine cannot be attributed to an increased regional myocardial blood flow during ischemia or reperfusion. "
01/01/1989 - "We assessed the efficacy of nisoldipine in the treatment of asymptomatic ischemia in 12 patients with chronic, stable angina. "
|2.||Hypertension (High Blood Pressure)
01/01/1999 - "Nisoldipine coat-core (nisoldipine CC), an extended-release once-daily formulation, is an effective treatment for mild-to-moderate hypertension, providing sustained blood pressure control over the 24-hour dosing interval. "
07/01/1990 - "We conclude that Nisoldipine is safe and effective in the treatment of mild essential hypertension."
09/01/1997 - "Canadian Nisoldipine CC Hypertension Trial Group."
03/01/1997 - "Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. "
04/01/1996 - "Twenty-four patients completed a dose ranging study of the effect of nisoldipine as monotherapy in the treatment of hypertension. "
11/01/1996 - "The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. "
11/01/1996 - "Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial."
04/27/1995 - "In patients with angina pectoris, nisoldipine CC improved total treadmill exercise duration (p = 0.027), delayed the onset of angina pectoris (p = 0.009), and increased time to exercise-induced ST-segment depression (p = 0.061). "
06/15/1994 - "Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris."
11/01/1996 - "In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
11/01/1989 - "The prolonged efficacy of nisoldipine could be favourable in oral long-term treatment of patients with coronary artery disease."
12/01/1985 - "These data demonstrated improved rest and exercise cardiac performance following nisoldipine in patients with severe coronary artery disease."
08/01/2003 - "The NICOLE study (NIsoldipine in COronary artery disease in LEuven) is a single centre, randomised, double blind, placebo controlled trial with coronary angiography at baseline, six months, and three years of follow up. "
08/01/2003 - "Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study."
08/01/2003 - "Nisoldipine has no demonstrable effect on the angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but its use is associated with fewer revascularisation procedures."
01/01/1997 - "DEFIANT-II: a study of nisoldipine CC after myocardial infarction. "
01/01/1997 - "The DEFIANT studies have demonstrated that nisoldipine CC improves cardiac function and exercise tolerance in patients recovering from acute myocardial infarction, without increasing the risk of mortality compared with placebo. "
01/01/1997 - "A multicentre, double-blind, placebo-controlled trial was conducted in 542 patients, randomized 7-10 days after myocardial infarction, to study the effect of nisoldipine coat-core (nisoldipine-CC) on exercise after 6 months. "
04/27/1995 - "In the Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy (DEFIANT-I) study of patients recovering from myocardial infarction, nisoldipine CC had a salutary effect on diastolic ventricular function, with a higher transmitral early filling velocity and shorter isovolumic relaxation time than in patients receiving placebo. "
04/27/1995 - "The aim of the present study was to evaluate whether oral nisoldipine can increase regional myocardial blood flow (MBF) in dyssynergic but viable myocardium after myocardial infarction. "
|4.||Calcium Channels (Calcium Channel)
|6.||Calcium Channel Blockers (Blockers, Calcium Channel)
|1.||Angioplasty (Angioplasty, Transluminal)
|3.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)